Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018

Symposium faculty to include Dmitriy Zamarin, MD, PhD, and Alexander N. Shoushtari, MD, medical oncologists from Memorial Sloan Kettering Cancer Center

Oslo, Norway, 27 September 2018 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is hosting a Key Opinion Leader (KOL) symposium in New York City on Thursday 11 October 2018, featuring two renowned immunotherapy experts from the Memorial Sloan Kettering Cancer Center.

The meeting will consist of presentations from world leading experts on oncolytic viruses, as well as presentations from the Targovax senior management team. Presentations and discussion will include an overview of oncolytic viruses in general and the potential of this emerging technology in the treatment of cancer, including how the engineered ONCOS adenovirus fits into the broader landscape.

The CMO of Targovax, Dr. Magnus Jäderberg, will also discuss the status of the ongoing ONCOS-102 clinical program, and Dr. Shoushtari will present interim data from the Phase I trial in checkpoint inhibitor (CPI) refractory advanced melanoma. Please see press release issued today for top-line results.

Symposium Faculty participants:

Dmitriy Zamarin, MD, PhD, Medical Oncologist, Memorial Sloan Kettering

Dr. Zamarin’s research is focused on the development of novel ways to use the immune system to treat cancer, including evaluation of novel immunotherapy drugs. He has published several landmark papers on oncolytic viruses and is the Study Chair on the ONCOS-102 trial in peritoneal cancer, in collaboration with Cancer Research Institute (CRI), Ludwig Cancer Research and MedImmune/AstraZeneca.

Alexander N. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering

Dr. Shoushtari is a renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He has been part of several immunotherapy trials at MSKCC and is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma.

Drs. Zamarin and Shoushtari are both members of the research team of Dr. Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service at the Memorial Sloan Kettering Cancer Center.

The event starts at 12:00 EST / 18:00 CET. A complete program agenda will be available shortly. A live webcast of the symposium will be available in the Events and Presentations section of the Targovax website.

To register for the event, please contact jporcelli@troutgroup.com or visit www.troutaccess.com.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert – FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com  

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.